{"id":"NCT04174599","sponsor":"EVIVE Biotechnology","briefTitle":"Study to Compare the Efficacy and Safety of F-627 and GRAN®","officialTitle":"A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of F-627 and GRAN® in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-12","primaryCompletion":"2019-01-24","completion":"2019-06-19","firstPosted":"2019-11-22","resultsPosted":"2025-04-20","lastUpdate":"2025-04-20"},"enrollment":242,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer","Neutropenia"],"interventions":[{"type":"DRUG","name":"F-627","otherNames":["Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein"]},{"type":"DRUG","name":"GRAN®","otherNames":["Filgrastim"]}],"arms":[{"label":"F-627","type":"EXPERIMENTAL"},{"label":"GRAN®","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein (F-627) and Recombinant Human Granulocyte Colony Stimulating Factor (GRAN®) in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia","primaryOutcome":{"measure":"Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1","timeFrame":"Cycle 1, the first of 4, 21-day chemotherapy cycles (average 3 weeks)","effectByArm":[{"arm":"F-627","deltaMin":0.68,"sd":1.1},{"arm":"GRAN®","deltaMin":0.71,"sd":0.967}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["39272058"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":120},"commonTop":["Nausea","White blood cell count decreased","Alopecia","Neutrophil count decreased","Vomiting"]}}